Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine plus lenalidomide in elderly untreated AML patients declining intensive induction
2008-006790-33Phase 2Completed
- Sponsor
- Cardarelli Hospital
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and cytarabine in acute myeloid leukemia (AML), sponsored by Cardarelli Hospital. Primary endpoint: Complete response rate (including CRi) per SWOG criteria. Started Apr 2009; status: completed.
02
Drugs
lenalidomidecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-006790-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006790-33.